ArticleInternational journal of dentistry2026
A Novel Synergistic Carvacrol-Graphene Oxide-Chitosan Nanocomposite for Effective Root Canal Disinfection.
Article in International journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Synergistic Carvacrol-Graphene Oxide-Chitosan Nanocomposite for Effective Root Canal Disinfection.International journal of dentistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Persistent microorganisms such as Materials/Methods: The CV@GO-CS nanocomposite was synthesized and evaluated for physicochemical properties, encapsulation efficiency (EE%), and release kinetics. Cytocompatibility was assessed using L929 fibroblast viability assays, and cell migration was evaluated by scratch tests. Antimicrobial efficacy was determined against Results: CV@GO-CS exhibited a hydrodynamic diameter of ~190 nm (polydispersity index [PDI] 0.24) and a zeta potential of + 22.3 mV. EE% and loading capacity (LC%) were 88.6% ± 3.6% and 46.9% ± 0.9%, respectively. CV release followed a biphasic profile, with ~45% released at 24 h and ~82% at 96 h. At a concentration of 50 µg/mL-which exceeds the determined minimum bactericidal/fungicidal concentrations-L929 fibroblast viability exceeded 95%, and wound closure was significantly enhanced compared with controls. Antimicrobial testing showed MIC/MBC values of 25 μg/mL against Conclusions: The CV@GO-CS nanocomposite demonstrated favorable physicochemical characteristics, high cytocompatibility, and strong antimicrobial activity against key endodontic pathogens. These findings support its potential as a sustainable, biocompatible platform for sustained-release root canal disinfectants or intracanal medicaments; however, efficacy against endodontic biofilms remains to be established, and further preclinical evaluation in biofilm and ex vivo models is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.